Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
126 hedge funds and large institutions have $782M invested in Adverum Biotechnologies in 2020 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 51 increasing their positions, 31 reducing their positions, and 19 closing their positions.
969% more call options, than puts
Call options by funds: $12.2M | Put options by funds: $1.14M
74% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 19
65% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 31
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
13% more capital invested
Capital invested by funds: $693M → $782M (+$89.3M)
9% more funds holding
Funds holding: 116 → 126 (+10)
7.31% more ownership
Funds ownership: 93.12% → 100.44% (+7.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$84.8M |
| 2 |
VVM
Versant Venture Management
San Francisco,
California
|
+$82.4M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$22.2M |
| 4 |
DM
Deerfield Management
New York
|
+$21.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$10.4M |
| 2 |
JP Morgan Chase
New York
|
-$6.06M |
| 3 |
Renaissance Technologies
New York
|
-$4.33M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.96M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.79M |
ADVM Hedge Fund Activity: Q1 2020 in Review
126 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q1 2020, worth a combined $782M — up 13% from $693M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ADVM positions and 19 closed out — a net gain of 14 holders — while 51 added to existing stakes and 31 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $84.8M. The largest seller was OrbiMed, cutting an estimated $10.4M.
- 126 institutional investors held Adverum Biotechnologies (ADVM) as of Q1 2020, up from 116 in Q4 2019.
- Funds reported $782M of Adverum Biotechnologies stock for Q1 2020, up 13% quarter-over-quarter.
- 33 funds opened new Adverum Biotechnologies positions in Q1 2020 and 19 closed out, a net change of +14 holders.
- The largest Adverum Biotechnologies buyer in Q1 2020 was RA Capital Management, an estimated $84.8M added.
- The largest Adverum Biotechnologies seller in Q1 2020 was OrbiMed, an estimated $10.4M sold.
Based on aggregated 13F filings for Q1 2020.